NAS:MDXH (Belgium)
Business Description
Compare
Compare
Traded in other countries / regions
MDXH.Belgium
•
O6C.Germany
•
0O8G.UK
•
MXDHF.USA
Description
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.78 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.48 | |||||
| Debt-to-EBITDA | -0.52 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -2.11 | |||||
| Beneish M-Score | -2.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -27.7 | |||||
| 3-Year EBITDA Growth Rate | 26.9 | |||||
| 3-Year EPS without NRI Growth Rate | 24.5 | |||||
| 3-Year FCF Growth Rate | 27.7 | |||||
| 3-Year Book Growth Rate | -29.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.35 | |||||
| 9-Day RSI | 50.21 | |||||
| 14-Day RSI | 47.16 | |||||
| 6-1 Month Momentum % | 1.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.38 | |||||
| Quick Ratio | 2.28 | |||||
| Cash Ratio | 1.91 | |||||
| Days Inventory | 53.11 | |||||
| Days Sales Outstanding | 66.99 | |||||
| Days Payable | 193.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -37.5 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 44.73 | |||||
| Operating Margin % | -128.26 | |||||
| Net Margin % | -137.94 | |||||
| ROE % | -106.37 | |||||
| ROA % | -58.07 | |||||
| ROIC % | -185.1 | |||||
| ROC (Joel Greenblatt) % | -697.84 | |||||
| ROCE % | -75.32 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.9 | |||||
| PB Ratio | 3.6 | |||||
| Price-to-Tangible-Book | 3.89 | |||||
| EV-to-EBIT | -2.6 | |||||
| EV-to-EBITDA | -2.88 | |||||
| EV-to-Revenue | 3.37 | |||||
| EV-to-Forward-Revenue | 1.2 | |||||
| EV-to-FCF | -3.12 | |||||
| Price-to-Median-PS-Value | 0.44 | |||||
| Price-to-Net-Current-Asset-Value | 5.2 | |||||
| Price-to-Net-Cash | 8.87 | |||||
| Earnings Yield (Greenblatt) % | -38.44 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MDXH
Peter Lynch Chart
Performance
Dividend
Annualized Return %
Total Annual Return %
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 24.517 | ||
| EPS (TTM) ($) | -2.4 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 47.16 | ||
| 14-Day ATR ($) | 0.427914 | ||
| 20-Day SMA ($) | 7.083325 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 6 - 13.17 | ||
| Shares Outstanding (Mil) | 16.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MDxHealth SA Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
MDxHealth SA Analysis
Share your researchHeadlines
See More
No news.